Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Veterans' PTSD study seeks best treatment match

NCT ID NCT04961190

Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three proven PTSD treatments—talk therapy (prolonged exposure), antidepressant medication (paroxetine or venlafaxine), and their combination—in 304 veterans. Researchers aim to identify which treatment works best for whom, using personalized algorithms. Participants receive up to 14 weeks of treatment and are followed for 40 weeks to track PTSD symptoms, depression, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
paroxetine (Paxil) or venlafaxine XR (Effexor XR)
What this could lead to
If successful, this study could help doctors choose the most effective PTSD treatment for each veteran, improving recovery and quality of life.
What could go wrong
This is a Phase 4 trial comparing existing treatments, so it won't introduce a new cure. Results may not apply to non-veterans or those with different trauma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

304 people

The number who actually took part.

Started

May 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * DSM-5 diagnosis of Posttraumatic Stress Disorder * military veteran * fluent in English * willing to participate in PE, pharmacotherapy, or both * capable of providing informed consent Exclusion Criteria: * suicidal ideation with intent and/or plan, or suicidal behavior in the past month * active psychosis * history of manic episode(s) * a failed trial of Prolonged Exposure therapy or paroxetine and venlafaxine XR * ongoing medical conditions or treatments that would contraindicate initiating these treatments (e.g., medications that have potential interactions with paroxetine and venlafaxine such as MAO inhibitors)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Posttraumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Posttraumatic stress disorder

Contacts and locations

Locations

  • Birmingham VA Healthcare System

    Birmingham, Alabama, 35233, United States

  • Coatesville VA Medicial Center

    Coatesville, Pennsylvania, 19320, United States

  • Corporal Michael J. Crescenz VA Medical Center

    Philadelphia, Pennsylvania, 19104, United States

  • Milwaukee VA Medical Center

    Milwaukee, Wisconsin, 53295, United States

  • VA North Texas Healthcare System

    Dallas, Texas, 75216, United States

  • VA Palo Alto Healthcare System

    Menlo Park, California, 94025, United States

  • VA San Diego Healthcare System

    San Diego, California, 92161, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.